文献速递核素与放射性配体治疗

靶向CD38的212Pb α放射免疫治疗在多发性骨髓瘤中的临床前研究

212Pb α-Radioimmunotherapy Targeting CD38 in Multiple Myeloma: A Preclinical Study.
PubMed 文献 · J Nucl Med · 2019-12-20

本研究在多发性骨髓瘤(MM)的体外和体内模型中评估了212Pb-daratumumab(抗人CD38)及抗小鼠CD38抗体的α放射免疫治疗潜力。体外实验显示212Pb-daratumumab显著抑制RPMI8226细胞增殖;体内生物分布显示特异性肿瘤摄取;在RPMI8226异种移植小鼠中,277.5 kBq 212Pb-daratumumab组中位生存期为55天,而磷酸盐缓冲液组为11天。结论认为212Pb-daratumumab在异种移植小鼠中有效,可显著缩小肿瘤并延长生存,突显α放射免疫治疗在多发性骨髓瘤治疗中的潜力。

要点

  • 212Pb-daratumumab在体外显著抑制人多发性骨髓瘤RPMI8226细胞系增殖。
  • 生物分布研究显示daratumumab在肿瘤中有特异性蓄积。
  • 277.5 kBq 212Pb-daratumumab组中位生存55天,磷酸盐缓冲液组为11天。

核心结论

  • 212Pb-daratumumab在异种移植小鼠中显示有效性,可见显著肿瘤消退和生存期延长。
  • 本研究突显α放射免疫治疗在多发性骨髓瘤治疗中的潜力。

研究设计与样本

  • 体外实验:将RPMI8226细胞系与递增活度(0.185-3.7 kBq/mL)的212Pb同型对照或212Pb-daratumumab共孵育,评估细胞增殖抑制。
  • 体内实验:通过SPECT/CT显像及处死后进行生物分布研究,并开展剂量范围探索和急性毒性研究。
  • 因daratumumab不结合小鼠CD38,另用抗小鼠CD38抗体进行生物分布和剂量范围探索。
  • 疗效实验:小鼠皮下接种5×10^6个RPMI8226细胞,接种后13天静脉注射212Pb-daratumumab或对照溶液,通过肿瘤体积测量和总生存评估疗效。

主要发现

  • 与212Pb同型对照或冷抗体相比,孵育3天后212Pb-daratumumab显著抑制人骨髓瘤RPMI8226细胞系增殖。
  • 生物分布研究显示daratumumab在肿瘤中有特异性蓄积。
  • 由于缺乏交叉反应性,212Pb-daratumumab在活度高达370 kBq时未观察到毒性。
  • 212Pb-抗小鼠CD38的急性毒性实验确定毒性活度为277.5 kBq。
  • 为在安全治疗活度范围内进行疗效研究,小鼠接受185 kBq或277.5 kBq的212Pb-daratumumab治疗。

关键数值与推荐

  • 体外增殖抑制实验:212Pb-daratumumab活度范围0.185-3.7 kBq/mL,孵育3天。
  • 急性毒性实验:212Pb-抗小鼠CD38确立毒性活度为277.5 kBq。
  • 疗效实验:小鼠皮下接种5×10^6个RPMI8226细胞,接种后13天给药,212Pb-daratumumab剂量为185 kBq或277.5 kBq。
  • 生存期:277.5 kBq 212Pb-daratumumab组中位生存55天 vs 磷酸盐缓冲液组11天。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is a plasma cell cancer and represents the second most frequent hematologic malignancy. Despite new treatments and protocols, including high-dose chemotherapy associated with autologous stem cell transplantation, the prognosis of MM patients is still poor. α-radioimmunotherapy (α-RIT) represents an attractive treatment strategy because of the high-linear-energy transfer and short pathlength of α-radiation in tissues, resulting in high tumor cell killing and low toxicity to surrounding tissues. In this study, we investigated the potential of α-RIT with 212Pb-daratumumab (anti-hCD38), in both in vitro and in vivo models, as well as an antimouse CD38 antibody using in vivo models. Methods: Inhibition of cell proliferation after incubation of the RPMI8226 cell line with an increasing activity (0.185-3.7 kBq/mL) of 212Pb-isotypic control or 212Pb-daratumumab was evaluated. Biodistribution was performed in vivo by SPECT/CT imaging and after death. Dose-range-finding and acute toxicity studies were conducted. Because daratumumab does not bind the murine CD38, biodistribution and dose-range finding were also determined using an antimurine CD38 antibody. To evaluate the in vivo efficacy of 212Pb-daratumumab, mice were engrafted subcutaneously with 5 × 106 RPMI8226 cells. Mice were treated 13 d after engraftment with an intravenous injection of 212Pb-daratumumab or control solution. Therapeutic efficacy was monitored by tumor volume measurements and overall survival. Results: Significant inhibition of proliferation of the human myeloma RPMI8226 cell line was observed after 3 d of incubation with 212Pb-daratumumab, compared with 212Pb-isotypic control or cold antibodies. Biodistribution studies showed a specific tumoral accumulation of daratumumab. No toxicity was observed with 212Pb-daratumumab up to 370 kBq because of lack of cross-reactivity. Nevertheless, acute toxicity experiments with 212Pb-anti-mCD38 established a toxic activity of 277.5 kBq. To remain within realistically safe treatment activities for efficacy studies, mice were treated with 185 kBq or 277.5 kBq of 212Pb-daratumumab. Marked tumor growth inhibition compared with controls was observed, with a median survival of 55 d for 277.5 kBq of 212Pb-daratumumab instead of 11 d for phosphate-buffered saline. Conclusion: These results showed 212Pb-daratumumab to have efficacy in xenografted mice, with significant tumor regression and increased survival. This study highlights the potency of α-RIT in MM treatment.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Quelven I, Monteil J, Sage M, et al. 212Pb α-Radioimmunotherapy Targeting CD38 in Multiple Myeloma: A Preclinical Study. J Nucl Med. 2019. PMID: 31862796. doi:10.2967/jnumed.119.239491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。